(lp0
S'Why Anacor Pharmaceuticals, Inc. Stock Jumped 58.3% in May Motley Fool - Jun 5, 2016 What: Shares of Anacor Pharmaceuticals, Inc. , a biopharmaceutical company discovering, developing, and commercializing novel small-molecule therapeutics, shot up 58.3% last month, according to data from S&amp;P Global Market&nbsp;...Anacor Postmortem - Seeking Alpha'
p1
aS'Apple Inc. and Anacor Pharmaceuticals Inc. Soar As Stocks Jump Motley Fool - May 16, 2016 After three consecutive weeks of declines, stocks started the new trading week on a much more positive note. On Monday, the Dow Jones Industrial Average  added 175 points, or 1%, and the S&amp;P 500  gained 20 points,&nbsp;...'
p2
aS"Pfizer's Buyout of Anacor Pharmaceuticals for $5.2 Billion Is a Bad Move ... Motley Fool - May 24, 2016 In fact, during Pfizer's quarterly conference call, CEO Ian Read stated that the company was actively looking at ways to boost its innovative business with late-stage and/or commercial products."
p3
aS"Why Anacor Pharmaceuticals, Inc.'s Stock Skyrocketed Today Motley Fool - Jul 13, 2015 What: Shares of Anacor Pharmaceuticals  rose by over 40% today on heavy volume after the company released positive top-line results from two pivotal late-stage trials for crisaborole topical ointment as a treatment for mild-to-moderate&nbsp;...Wedbush On Anacor Pharma: Crisaborole Delivers, Reiterate Outperform - BenzingaAnacor Pharmaceuticals Inc  May Have A Home Run Drug On Its Hands - Smarter Analyst"
p4
aS'Pfizer buying Anacor Pharmaceuticals in $5.2-billion deal Los Angeles Times - May 16, 2016 Pfizer Inc. is acquiring Anacor Pharmaceuticals Inc., a California company with a potentially lucrative eczema treatment, in a deal valued at about $5.2 billion.'
p5
aS'Why Anacor Pharmaceuticals, Inc. Shot Higher Motley Fool - Mar 13, 2015 What: Shares in Anacor Pharmaceuticals  jumped by more than 15% today after reporting fourth quarter sales and earnings that eclipsed Wall Street forecasts.'
p6
aS"Why Anacor Pharmaceuticals Rocketed 93% Higher in July Motley Fool - Aug 5, 2015 What: After the company reported positive top-line results from two key phase 3 studies, growing enthusiasm for drugs discovered by Anacor Pharmaceuticals'  boron chemistry platform sent the company's shares soaring by 92.7% in July."
p7
aS"Anacor Pharmaceuticals Is Too Expensive Seeking Alpha - Jan 19, 2016 Sandoz is responsible for Kerydin's commercialization and Anacor is entitled to 50% of gross profit  and the company received $20 million in Q3 as Sandoz generated $40 million in sales. This represents an annual run rate ..."
p8
aS"Anacor Pharmaceuticals: The Devil You Don't Know Seeking Alpha - Jul 18, 2015 Anacor  is working toward bringing its boron-based topical anti-inflammatory phosphodiesterase 4 inhibitor  to the market."
p9
aS'With 365% stock climb, this Bay Area drug maker has skin in the game San Francisco Business Times  - Jul 31, 2015 Much of the stock boom came this month, after Palo Alto-based Anacor  announced early data from two studies of crisaborole - formerly known as AN-2728 - in people with raised, red, itchy and oozing blotches also known as atopic&nbsp;...'
p10
a.